c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth factor, activates a wide range of different cellular signaling pathways, including those involved in …

MET transcription is activated by HGF and several growth factors. [42] MET promoter has four putative binding sites for Ets, a family of transcription factors that control several invasive …

Jul 1, 2021 · C-MET can be activated by either hepatocyte growth factor (HGF), or its natural isoform NK1. Here, we report the cryo-EM structures of c-MET/HGF and c-MET/NK1 …

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These …

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This …

Feb 19, 2018 · In this review, we elaborate on the molecular structure of c-Met and HGF and the mechanism through which their interaction activates the PI3K/AKT, Ras/MAPK, and Wnt …

Jun 18, 2021 · This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor (HGF) /mesenchymal–epithelial transition factor (c-MET)) signaling pathway in …

C-Met is a receptor tyrosine kinase (RTK) that consists of an extracellular alpha chain and a beta subunit. It is activated by its ligand hepatocyte growth factor (HGF), leading to phosphorylation …

Activation of c-Met signaling can lead to scattering, angiogenesis, proliferation, enhanced cell motility, invasion, and eventual metastasis. In this review, the role of c-Met dysregulation in …

Jul 21, 2023 · MET amplification is a common mechanism known to drive c-Met overexpression that can occur de novo in treatment-naïve patients and can emerge after treatment with TKIs, …